drugset / Trial / NCT00374907

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907

Phase 3 Completed 156 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes

Timeline

Start
2006-09
Primary completion
2008-01
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Comparator Metformin Small molecule 500 mg Oral
Comparator Metformin Small molecule 1000 mg Oral
Comparator Metformin Small molecule 1500 mg Oral